OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Autoimmunity is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Safety of biologic immunosuppressants in pregnant women with immune-mediated inflammatory diseases	412
The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial	227
Janus kinase inhibition prevents autoimmune diabetes in LEW.1WR1 rats	190
Advances in SLE classification criteria	151
Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination	140
ATP-binding cassette G1 membrane transporter-mediated cholesterol efflux capacity influences coronary atherosclerosis and cardiovascular risk in Rheumatoid Arthritis	128
HNF4α, SP1 and c-myc are master regulators of CNS autoimmunity	119
GILZ regulates type I interferon release and sequesters STAT1	110
Autoimmune associated HLAs and T cell autoantigens exhibit common patterns across several autoimmune diseases	105
Differences in innate immune cell populations distinguish autoimmune from herpesvirus-associated encephalitis	101
Ectopic CD4+ T cells in choroid plexus mediate neuropsychiatric lupus symptoms in mice via interferon-γ induced microglia activation	98
Immunological and fibrotic profiling in the NOD.c3c4 murine model of autoimmune cholangitis	94
Editorial Board	89
Tfh cell-derived small extracellular vesicles exacerbate the severity of collagen-induced arthritis by enhancing B-cell responses	89
Autoreactivity to self-antigens LL37 and ADAMTSL5 influences the clinical response to risankizumab in psoriatic patients	85
Global and regional epidemiology of psoriatic arthritis in patients with psoriasis: A comprehensive systematic analysis and modelling study	82
Breach of tolerance versus burden of bile acids: Resolving the conundrum in the immunopathogenesis and natural history of primary biliary cholangitis	82
Lupus nephritis: new progress in diagnosis and treatment	75
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations	73
Anti-annexin A4 antibody as a biomarker for desquamative interstitial pneumonia	70
Earlier vs. later time period of COVID-19 infection and emergent autoimmune signs, symptoms, and serologies	68
FAPI PET/CT for tracking disease trajectory in myositis-related interstitial lung disease	63
Post-translationally modified proteins bind and activate complement with implications for cellular uptake and autoantibody formation	62
Cellular communication network factor 3 contributes to the pathological process of rheumatoid arthritis through promoting cell senescence and osteoclastogenesis in the joint	56
Interferon signatures fuel B cell hyperactivity and plasmablast expansion in systemic lupus erythematosus	50

Intracellular virus sensor MDA5 mutation develops autoimmune myocarditis and nephritis	49
Genetic and transcriptomic analyses support a switch to lytic phase in Epstein Barr virus infection as an important driver in developing Systemic Lupus Erythematosus	47
Editorial Board	47
Editorial Board	47
LAT1 enables T cell activation under inflammatory conditions	47
Editorial Board	46
Autoantibodies against a subunit of mitochondrial respiratory chain complex I in inclusion body myositis	46
Glycobiology of psoriasis: A review	45
Sunscreen use associated with elevated prevalence of anti-nuclear antibodies in U.S. adults	45
Identification of the central tolerance checkpoint for autoreactive proteinase 3+ B cells in human bone marrow	44
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort	43
Whole blood transcriptome identifies interferon-regulated genes as key drivers in thrombotic primary antiphospholipid syndrome	39
Targeting macrophages with phosphatidylserine-rich liposomes as a potential antigen-specific immunotherapy for type 1 diabetes	38